Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | FGR | P09769 | 1/20 | 1.00 |
| ▸ | TEC | P42680 | 1/20 | 1.00 |
| ▸ | BMX | P51813 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SLK | Q9H2G2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354649 | 1.00 | BTK (1.00) | BTKYES1FGRTECBMX | |
| SCHEMBL1724904 | 1.00 | BTK (1.00) | BTKYES1FGRTECBMX | |
| SCHEMBL16173690 | 0.96 | BTK (0.93) | BTKYES1FGRTECBMX | |
| SCHEMBL1726979 | 0.94 | BTK (1.00) | BTKYES1FGRTECBMX | |
| SCHEMBL22945745 | 0.94 | BTK (0.92) | BTKYES1FGRTECBMX | |
| SCHEMBL22946024 | 0.94 | BTK (0.89) | BTKYES1FGRTECBMX | |
| SCHEMBL3041622 | 0.94 | BTK (0.88) | BTKYES1FGRTECBMX | |
| SCHEMBL3058691 | 0.93 | BTK (0.87) | BTKYES1FGRTECBMX | |
| SCHEMBL1727048 | 0.93 | BTK (1.00) | BTKYES1FGRTECBMX | |
| SCHEMBL22946141 | 0.92 | BTK (0.87) | BTKYES1FGRTECBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022232420-A1 | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CANCER | INSMED INCORPORATED (US) | 2022-11-03 | — | — | WO | claimed |
| WO-2022081512-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF NEUROINFLAMMATORY DISEASES WITH BRUTON'S TYROSINE KINASE INHIBITORS | SYNUBI PHARMACEUTICALS LLC (US) | 2022-04-21 | — | — | WO | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260041685-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | TELIOS PHARMA INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4665720-A2 | ISOINDOLINONE GLUTARIMIDE AND PHENYL GLUTARIMIDE ANALOGS AS DEGRADERS OF RET KINASE | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4652997-A2 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | Pharmacosmos Holding A/s (DK) | 2025-11-26 | — | — | EP | disclosed |
| US-12414950-B1 | Methods of treating indolent systemic mastocytosis | TELIOS PHARMA INC. (US) | 2025-09-16 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081512-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF NEUROINFLAMMATORY DISEASES WITH BRUTON'S TYROSINE KINASE INHIBITORS | SYNUBI PHARMACEUTICALS LLC (US) | 2022-04-21 | — | — | WO | disclosed |
| CN-105682658-B | Cancer therapy using PI3 kinase subtype modulators | 无限药品公司 | 2022-04-05 | — | — | CN | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022035997-A1 | IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS | AVILAR THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022032132-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022032026-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041685-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | BTK, KIT, LYN | BTK 1/4885YES1 15/4885FGR 233/4885 |
| US-12414950-B1 | Methods of treating indolent systemic mastocytosis | BTK, LYN, ABL1 | BTK 1/4885YES1 50/4885FGR 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.